{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:03:31Z","timestamp":1780470211442,"version":"3.54.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/rhu.0b013e31823ecd73","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T17:58:28Z","timestamp":1355767108000},"page":"92-95","source":"Crossref","is-referenced-by-count":44,"title":["Successful Use of Interleukin 6 Antagonist Tocilizumab in a Patient With Refractory Cutaneous Lupus and Urticarial Vasculitis"],"prefix":"10.1097","volume":"18","author":[{"given":"Ashima","family":"Makol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence E.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement J.","family":"Michet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210207","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/berh.2001.0224","article-title":"Management of skin disease in patients with lupus erythematosus.","volume":"16","author":"Callen","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R2-7-20210207","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000112938","article-title":". Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case.","volume":"216","author":"Uthman","year":"2008","journal-title":"Dermatology"},{"key":"R3-7-20210207","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1440-0960.2009.00539.x","article-title":". Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab.","volume":"50","author":"Kieu","year":"2009","journal-title":"Australas J Dermatol"},{"key":"R4-7-20210207","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":". Interleukin-6 as a key player in systemic inflammation and joint destruction.","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"suppl 2","key":"R5-7-20210207","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1918","article-title":"Interleukin-6 and rheumatic diseases.","volume":"8","author":"Lipsky","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R6-7-20210207","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/eji.1830230515","article-title":". Serum soluble interleukin-6 receptor in MRLlpr mice is elevated with age and mediates the interleukin-6 signal.","volume":"23","author":"Suzuki","year":"1993","journal-title":"Eur J Immunol"},{"key":"R7-7-20210207","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/intimm\/3.3.273","article-title":". Age-associated increase in interleukin 6 in MRLlpr mice.","volume":"3","author":"Tang","year":"1991","journal-title":"Int Immunol"},{"key":"R8-7-20210207","first-page":"927","article-title":". Interleukin-6 exacerbates glomerulonephritis in (NZB NZW)F1 mice.","volume":"144","author":"Ryffel","year":"1994","journal-title":"Am J Pathol"},{"key":"R9-7-20210207","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI117373","article-title":"Interleukin 6 promotes murine lupus in NZBNZW F1 mice.","volume":"94","author":"Finck","year":"1994","journal-title":"J Clin Invest"},{"key":"R10-7-20210207","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2006.02433.x","article-title":". Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.","volume":"119","author":"Liang","year":"2006","journal-title":"Immunology"},{"key":"R11-7-20210207","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1998.00612.x","article-title":". IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZBW F1 mice.","volume":"112","author":"Mihara","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"R12-7-20210207","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","article-title":". Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus.","volume":"27","author":"Chun","year":"2007","journal-title":"J Clin Immunol"},{"key":"R13-7-20210207","first-page":"565","article-title":". Cytokine production, serum levels and disease activity in systemic lupus erythematosus.","volume":"18","author":"Grondal","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"R14-7-20210207","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/096120339600500603","article-title":"Serum and urinary interleukin-6 in systemic lupus erythematosus.","volume":"5","author":"Peterson","year":"1996","journal-title":"Lupus"},{"key":"R15-7-20210207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","article-title":". Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis.","volume":"147","author":"Linker-Israeli","year":"1991","journal-title":"J Immunol"},{"key":"R16-7-20210207","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/art.1780340305","article-title":". In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells.","volume":"34","author":"Klashman","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R17-7-20210207","first-page":"16","article-title":". Urinary levels of IL-6 in patients with active lupus nephritis.","volume":"40","author":"Iwano","year":"1993","journal-title":"Clin Nephrol"},{"key":"R18-7-20210207","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000045663","article-title":". Increased excretions of 2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis.","volume":"85","author":"Tsai","year":"2000","journal-title":"Nephron"},{"key":"R19-7-20210207","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":". Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e31823ecd73","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T12:14:52Z","timestamp":1714738492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201203000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31823ecd73","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}